Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- HRS-1 (US label, creatinine-guided):
- Days 1–3: Terlipressin 0.85 mg IV every 6 hours (1 vial).
- Day 4: Assess SCr versus baseline.
- If SCr decreased ≥30% from baseline: continue 0.85 mg IV every 6 hours.
- If SCr decreased <30%: may increase to 1.7 mg IV every 6 hours.
- If SCr at or above baseline: discontinue.
- Continue until 24 hours after two consecutive SCr ≤1.5 mg/dL (≥2 h apart) or maximum 14 days.
- SCr >5 mg/dL: limitation of benefit, not a dosing branch.
- Administered in ICU/hospital setting. Monitor oxygenation, ischemia, fluid status.